Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Combination Therapy Could Be Effective Against Ovarian Cancer

XTALKS VITALS NEWS

Combination Therapy

According to the study authors, the triple drug combination therapy could be an effective treatment option for patients whose cancer has developed resistance to chemotherapy and other conventional treatments.

Share this!

November 3, 2016 | by Sarah Hand, M.Sc.

Researchers at Boston University School of Medicine have identified a combination therapy which may be effective against certain types of ovarian cancer. The research was published in the journal, Anticancer Research.

According to the study authors, the triple drug combination therapy could be an effective treatment option for patients whose cancer has developed resistance to chemotherapy and other conventional treatments. The therapy combines a calpain inhibitor, known as calpeptin, with two different histone deacetylase inhibitors, sodium butyrate and suberanilohydroxamic acid (SAHA).

The researchers tested this combination in two ovarian cancer cell lines, CAOV-3 and SKOV-3. They found that this combination therapy was able to inhibit ovarian cancer cell growth, and induce apoptosis in the tumor cells.

While ovarian cancer accounts for just three percent of all cancers affecting women, it is responsible for the majority of cancer deaths when compared to other female reproductive system cancers. Ovarian cancer is often diagnosed after it has metastasized within the pelvis and abdomen, making it harder to treat and often fatal.



Surgery and chemotherapy are the frontline treatments for ovarian cancer. Platinum-based drugs are also commonly used to treat the disease, as few target specific drugs are approved for ovarian cancer.

Interestingly, calpeptin was also found to have epigenetic effects on the cells used in this study. The calpain inhibitor was able to remove methyl tags from select genes.

“Calpeptin possibly has a dual role,” said senior study author Dr. Sibaji Sarkar, of the Cancer Center, Genome Science Institute, Department of Medicine, Boston University School of Medicine. “It can kill cancer cells and in addition, it may act as an epigenetic drug as well.

“We believe that epigenetic drugs alone are not the best choice for cancer therapy. We need other target specific and other types of inhibitors, but the addition of epigenetic drugs can increase the efficacy of the therapy by blocking the expression of growth promoting genes even after remission after standard therapy.”

Previous research conducted by Sakar and colleagues has found that epigenetics play a key role in the generation of cancer progenitor cells, tumor progression and migration, as well as cancer drug resistance. Other studies have supported this idea by showing that epigenetic drugs make drug resistant cancer cells more susceptible to platinum therapies.


Keywords: Combination Therapy, Ovarian Cancer, Epigenetics


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News


FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News


Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Technology Solutions for Late Phase Research: Optimising Real World Data Assets


Serialization for Late Starters – With Live Industry Research Results


Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse


The New Gold Standards of IRT Delivery for Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.